ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Indegene delivered its strongest Q1 growth in four years, yet remains burdened by elevated costs from strategic investments and workforce transformation.
Indegene reported Q1'FY27 revenue of ₹10,631M (+39.7% YoY) with an EBITDA margin of 16.9%. The strategy focuses on scaling GenAI-powered solutions and deepening engagement with large pharma.
Indegene reported FY26 revenue of INR 35,105M with 19.4% adjusted EBITDA margin, positioning itself as an AI-embedded specialist displacing traditional agencies and CROs in life sciences.
Indegene positions as an AI-embedded operating partner for life sciences. Reported FY26 revenue of INR 35.1Bn with 19.4% EBITDA margins and 29.4% CAGR.
Indegene crossed ₹1,000Cr quarterly revenue milestone in Q4FY26. Strategy focuses on GenAI-led transformation (Tectonic model) and deepening top-20 global pharma relationships.
Indegene crossed the ₹1000cr quarterly revenue milestone for the first time in Q4FY26, though PAT was slightly dragged by exceptional legal provisions.
Indegene delivered strong FY26 revenue of INR 35,105M (+23.6% YoY) with steady 19.4% EBITDA margins, driven by GenAI-led transformation in life sciences.